Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:ALKS NASDAQ:EIDX NASDAQ:PCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$36.42-0.8%$37.74$23.42▼$62.58$2.12B0.87718,694 shs621,660 shsALKSAlkermes$27.89+1.8%$28.13$25.17▼$36.45$4.60B0.531.80 million shs2.25 million shsEIDXEidos Therapeutics$122.21$123.21$28.39▼$132.54$4.75B-0.16128,113 shsN/APCRXPacira BioSciences$26.03-1.8%$24.45$13.78▼$27.64$1.17B0.42787,937 shs520,097 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+1.16%+1.58%-0.78%+3.44%-19.14%ALKSAlkermes+3.28%-1.65%-5.71%-6.61%-1.58%EIDXEidos Therapeutics0.00%0.00%0.00%0.00%0.00%PCRXPacira BioSciences-1.30%+0.80%+6.98%+9.77%+96.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$36.42-0.8%$37.74$23.42▼$62.58$2.12B0.87718,694 shs621,660 shsALKSAlkermes$27.89+1.8%$28.13$25.17▼$36.45$4.60B0.531.80 million shs2.25 million shsEIDXEidos Therapeutics$122.21$123.21$28.39▼$132.54$4.75B-0.16128,113 shsN/APCRXPacira BioSciences$26.03-1.8%$24.45$13.78▼$27.64$1.17B0.42787,937 shs520,097 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+1.16%+1.58%-0.78%+3.44%-19.14%ALKSAlkermes+3.28%-1.65%-5.71%-6.61%-1.58%EIDXEidos Therapeutics0.00%0.00%0.00%0.00%0.00%PCRXPacira BioSciences-1.30%+0.80%+6.98%+9.77%+96.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.75Moderate Buy$56.0053.76% UpsideALKSAlkermes 2.92Moderate Buy$41.8550.04% UpsideEIDXEidos Therapeutics 0.00N/AN/AN/APCRXPacira BioSciences 2.71Moderate Buy$30.8318.45% UpsideCurrent Analyst Ratings BreakdownLatest ALKS, EIDX, AGIO, and PCRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$43.009/9/2025ALKSAlkermesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$34.00 ➝ $35.009/9/2025ALKSAlkermesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$46.009/4/2025AGIOAgios PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$56.009/3/2025ALKSAlkermesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/2/2025ALKSAlkermesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$44.008/14/2025PCRXPacira BioSciencesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold7/30/2025ALKSAlkermesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$40.00 ➝ $42.007/29/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.007/28/2025AGIOAgios PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Outperform$71.00 ➝ $65.007/25/2025PCRXPacira BioSciencesTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$30.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$36.50M57.97N/AN/A$27.02 per share1.35ALKSAlkermes$1.56B2.96$2.79 per share10.00$9.05 per share3.08EIDXEidos Therapeutics$26.69M177.99N/AN/A$4.57 per share26.74PCRXPacira BioSciences$700.97M1.67$4.18 per share6.22$16.86 per share1.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.003.31N/AN/A1,590.42%-3.49%-3.23%10/30/2025 (Estimated)ALKSAlkermes$367.07M$2.0813.4120.361.4923.15%24.86%17.14%10/23/2025 (Estimated)EIDXEidos Therapeutics-$37.83M-$1.03N/AN/AN/AN/A-65.21%-53.04%N/APCRXPacira BioSciences-$99.56M-$2.78N/A10.13N/A-18.08%13.29%6.61%11/5/2025 (Estimated)Latest ALKS, EIDX, AGIO, and PCRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025PCRXPacira BioSciences$0.73$0.74+$0.01-$0.11$183.11 million$181.10 million7/31/2025Q2 2025AGIOAgios Pharmaceuticals-$1.74-$1.93-$0.19-$1.93$9.46 million$12.50 million7/29/2025Q2 2025ALKSAlkermes$0.42$0.52+$0.10$0.52$343.20 million$390.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AALKSAlkermesN/AN/AN/AN/AN/AEIDXEidos TherapeuticsN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.4814.04ALKSAlkermesN/A3.232.85EIDXEidos Therapeutics0.1411.1011.10PCRXPacira BioSciences0.502.381.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AALKSAlkermes95.21%EIDXEidos Therapeutics31.40%PCRXPacira BioSciences99.73%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.93%ALKSAlkermes4.40%EIDXEidos Therapeutics70.10%PCRXPacira BioSciences6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39058.10 million55.24 millionOptionableALKSAlkermes1,800165.08 million157.82 millionOptionableEIDXEidos Therapeutics7038.87 millionN/ANot OptionablePCRXPacira BioSciences72044.93 million42.06 millionOptionableALKS, EIDX, AGIO, and PCRX HeadlinesRecent News About These CompaniesRhumbline Advisers Sells 9,754 Shares of Pacira BioSciences, Inc. $PCRXSeptember 17 at 3:28 AM | marketbeat.com51,764 Shares in Pacira BioSciences, Inc. $PCRX Bought by Caxton Associates LLPSeptember 12, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Boosts Stock Position in Pacira BioSciences, Inc. $PCRXSeptember 9, 2025 | marketbeat.comPacira reports inducement grants under Nasdaq listing ruleSeptember 6, 2025 | msn.comBridgeway Capital Management LLC Buys 69,744 Shares of Pacira BioSciences, Inc. $PCRXSeptember 6, 2025 | marketbeat.comAlyeska Investment Group L.P. Takes $32.51 Million Position in Pacira BioSciences, Inc. $PCRXSeptember 6, 2025 | marketbeat.comRafferty Asset Management LLC Takes $251,000 Position in Pacira BioSciences, Inc. $PCRXSeptember 6, 2025 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Hits New 1-Year High - Here's What HappenedSeptember 5, 2025 | marketbeat.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comPDT Partners LLC Has $5.14 Million Stock Position in Pacira BioSciences, Inc. $PCRXSeptember 3, 2025 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Moderate Buy" from AnalystsSeptember 2, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Shares Acquired by Doma Perpetual Capital Management LLCSeptember 1, 2025 | marketbeat.com9,457 Shares in Pacira BioSciences, Inc. $PCRX Acquired by FORA Capital LLCSeptember 1, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Holdings Lifted by Walleye Capital LLCAugust 30, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Shares Bought by Wellington Management Group LLPAugust 29, 2025 | marketbeat.comQuantbot Technologies LP Purchases 24,102 Shares of Pacira BioSciences, Inc. $PCRXAugust 28, 2025 | marketbeat.comMartingale Asset Management L P Takes Position in Pacira BioSciences, Inc. $PCRXAugust 27, 2025 | marketbeat.comAmerican Century Companies Inc. Increases Holdings in Pacira BioSciences, Inc. $PCRXAugust 27, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Grows Stock Holdings in Pacira BioSciences, Inc. $PCRXAugust 26, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Shares Bought by Invesco Ltd.August 25, 2025 | marketbeat.comNuveen LLC Makes New Investment in Pacira BioSciences, Inc. $PCRXAugust 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALKS, EIDX, AGIO, and PCRX Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$36.42 -0.30 (-0.82%) Closing price 04:00 PM EasternExtended Trading$36.44 +0.02 (+0.05%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Alkermes NASDAQ:ALKS$27.89 +0.50 (+1.83%) Closing price 04:00 PM EasternExtended Trading$27.89 0.00 (0.00%) As of 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Eidos Therapeutics NASDAQ:EIDXEidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.Pacira BioSciences NASDAQ:PCRX$26.03 -0.48 (-1.81%) Closing price 04:00 PM EasternExtended Trading$26.06 +0.03 (+0.12%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
